A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of BA1201 for the treatment of advanced solid tumors
Latest Information Update: 19 Dec 2021
At a glance
- Drugs BA 1201 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shandong Boan Biotechnology
- 19 Dec 2021 New trial record
- 14 Dec 2021 According to Boan Biotechs media release, the clinical trial application for BA1201, has been approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA); an investigational new drug(IND) is also approved for BA 1201 by the NMPA for clinical trials.